CO2024005131A2 - Control angiogénico, preferiblemente combinado con control glucémico. - Google Patents

Control angiogénico, preferiblemente combinado con control glucémico.

Info

Publication number
CO2024005131A2
CO2024005131A2 CONC2024/0005131A CO2024005131A CO2024005131A2 CO 2024005131 A2 CO2024005131 A2 CO 2024005131A2 CO 2024005131 A CO2024005131 A CO 2024005131A CO 2024005131 A2 CO2024005131 A2 CO 2024005131A2
Authority
CO
Colombia
Prior art keywords
control
angiogenic
preferably combined
mtor
glycemic
Prior art date
Application number
CONC2024/0005131A
Other languages
English (en)
Inventor
Gert Wensvoort
Original Assignee
Biotempt Bv
Resiliun B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv, Resiliun B V filed Critical Biotempt Bv
Publication of CO2024005131A2 publication Critical patent/CO2024005131A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una distintiva clase de fármacos recientemente desarrollada: moduladores peptídicos de mTOR que actúan como compuestos inhibidores de la autofagia y se dirigen al sistema de detección de nutrientes de la diana mecanicista de la rapamicina (mTOR) e inducen actividad angiogénica. La invención proporciona formulaciones, métodos y medios para prevenir o tratar la vasculopatía, en particular la vasculopatía diabética, para lograr o mantener el control angiogénico, preferiblemente concomitante con el control glucémico.
CONC2024/0005131A 2021-10-05 2024-04-24 Control angiogénico, preferiblemente combinado con control glucémico. CO2024005131A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252488P 2021-10-05 2021-10-05
PCT/NL2022/050558 WO2023059188A1 (en) 2021-10-05 2022-10-05 Angiogenic control, preferably combined with glycaemic control.

Publications (1)

Publication Number Publication Date
CO2024005131A2 true CO2024005131A2 (es) 2024-05-30

Family

ID=83692933

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0005131A CO2024005131A2 (es) 2021-10-05 2024-04-24 Control angiogénico, preferiblemente combinado con control glucémico.

Country Status (5)

Country Link
KR (1) KR20240073966A (es)
AU (1) AU2022359382A1 (es)
CA (1) CA3234504A1 (es)
CO (1) CO2024005131A2 (es)
WO (1) WO2023059188A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024014953A1 (en) * 2022-07-12 2024-01-18 Resiliun B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
US8310981B2 (en) 2008-10-22 2012-11-13 Qualcomm Incorporated Common and dedicated modulation and coding scheme for a multicarrier system
SG11201906943VA (en) * 2017-02-06 2019-08-27 Biotempt Bv Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
MX2022002476A (es) * 2019-08-30 2022-08-10 Biotempt Bv Peptido q-er.
US20220370543A1 (en) * 2019-09-30 2022-11-24 Ebi Anti Sepsis B.V. Methods of treatment for modifying hemodynamics
WO2022069576A1 (en) * 2020-09-30 2022-04-07 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability

Also Published As

Publication number Publication date
WO2023059188A1 (en) 2023-04-13
AU2022359382A1 (en) 2024-05-02
CA3234504A1 (en) 2023-04-13
KR20240073966A (ko) 2024-05-27

Similar Documents

Publication Publication Date Title
CO2024005131A2 (es) Control angiogénico, preferiblemente combinado con control glucémico.
ECSP18081922A (es) Apósitos para heridas modificados
Tate et al. An update on the NLRP3 inflammasome and influenza: the road to redemption or perdition?
Kawanami et al. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
CL2015003442A1 (es) Derivados heterociclicos
CY1109353T1 (el) Ερυθροκυτταρα που περιεχουν αποϊμιναση αργινινης
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
CR20150217A (es) Inhibidores de histona demetilasas
MX2016015511A (es) Compuestos que comprenden grupo auto-destructivo.
AR063446A1 (es) Sistema de administracion para el tratamiento remoto de un animal
BR112014017095A2 (pt) composto, composição farmacêutica, método para regular atividade de proteína de uma proteína alvo, método para tratar um estado ou condição da doença, biblioteca de um composto, método para degradar uma proteína alvo, e, uso de um composto
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
BR112012027651A2 (pt) método, e, sistema
CR11295A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112014009992A2 (pt) sistema de preservação de movimento intersegmental para utilização na espinha e métodos para a sua utilização
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
BRPI0510697A (pt) gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete
CL2012001597A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular.
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
CL2011003079A1 (es) Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes.
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112018073205A2 (pt) método de microdiluição em caldo para avaliação e determinação da concentração inibitória mínima de polipeptídeos antibacterianos